» Articles » PMID: 31736916

A Novel In-House Enzyme-Linked Immunosorbent Assay for Genotype 3 Hepatitis E Virus Reveals High Seroprevalence in Blood Donors in Northern Argentina

Overview
Journal Front Microbiol
Specialty Microbiology
Date 2019 Nov 19
PMID 31736916
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The Hepatitis E virus (HEV) is an emergent virus that causes acute hepatitis in immunocompetent hosts and chronic hepatitis in immunocompromised hosts. In Latin America, the main circulating genotype HEV-3 is usually of zoonotic origin. Diagnosis and seroprevalence studies mainly rely on the detection of specific antibodies. There are scarce data on the seroprevalence of HEV infection in Latin America mainly due to the lack of awareness of HEV circulation. Furthermore, in some countries, like Argentina, HEV testing is not included in routine assays. In order to provide tools to deepen the knowledge on HEV epidemiology in South America, we designed a new in-house ELISA based on the native recombinant protein ORF2 aa112-608 and demonstrated its potential for detecting anti-HEV immunoglobulin G (IgG) in human serum samples. The following conditions were determined: an optimal antigen concentration of 0.25 μg/ml, a serum dilution of 1:80, gelatin as a blocking agent, and a secondary antibody dilution of 1:2000. A relative sensitivity of 93.33% (95% CI: 77.9-99.2%) and a relative specificity of 99.4% (95% CI: 96.7-100%) were determined using a panel of previously characterized sera and a gold standard (HEV IgG ELISA, DIA.PRO, Italy). Further, we obtained a very good agreement ( index = 0.94, 95% CI: 0.87-1.00) with the gold standard. We screened 813 blood donor samples with this newly developed ELISA and found a seroprevalence of 9.23% (95% confidence interval, 7.33-11.43%). We show for the first time evidence of past HEV infection in Tucuman, the most populated city in northern Argentina. We expect that this study will raise the interest of health decision makers who should intercede to include indirect testing of HEV in regular diagnostic protocols. In conclusion, the in-house ELISA developed in this work shows a very good agreement with an already licensed commercial HEV IgG ELISA (DIA.PRO, ITALY), which can be used as an epidemiologic tool for HEV surveillance.

Citing Articles

Exploring hepatitis E virus seroprevalence and associated risk factors among the human population in Tandil, Buenos Aires, Argentina.

Rivero M, Arce L, Gutierrez S, Tisnes A, Passucci J, Silva J Front Public Health. 2023; 11:1257754.

PMID: 37869189 PMC: 10585172. DOI: 10.3389/fpubh.2023.1257754.


A multispecies competitive nanobody-based ELISA for the detection of antibodies against hepatitis E virus.

Arce L, Pavan M, Bok M, Gutierrez S, Estein S, Tammone Santos A Sci Rep. 2023; 13(1):15448.

PMID: 37723180 PMC: 10507121. DOI: 10.1038/s41598-023-41955-z.


Higher Risk of HEV Transmission and Exposure among Blood Donors in Europe and Asia in Comparison to North America: A Meta-Analysis.

Wolski A, Pischke S, Ozga A, Addo M, Horvatits T Pathogens. 2023; 12(3).

PMID: 36986347 PMC: 10059948. DOI: 10.3390/pathogens12030425.


Development and Optimization of an Enzyme Immunoassay to Detect Serum Antibodies against the Hepatitis E Virus in Pigs, Using Plant-Derived ORF2 Recombinant Protein.

Takova K, Koynarski T, Minkov G, Toneva V, Mardanova E, Ravin N Vaccines (Basel). 2021; 9(9).

PMID: 34579228 PMC: 8473109. DOI: 10.3390/vaccines9090991.


Hepatitis E Virus Infection: Is It Really a Problem in Latin America?.

Pisano M, Mirazo S, Re V Clin Liver Dis (Hoboken). 2020; 16(3):108-113.

PMID: 33005391 PMC: 7508784. DOI: 10.1002/cld.931.


References
1.
Munne M, Altabert N, Otegui M L, Vladimirsky S, Moreiro R, Espul M . Updating the knowledge of hepatitis E: new variants and higher prevalence of anti-HEV in Argentina. Ann Hepatol. 2014; 13(5):496-502. View

2.
Debes J, Martinez Wassaf M, Pisano M, Isa M, Lotto M, Marianelli L . Increased Hepatitis E Virus Seroprevalence Correlates with Lower CD4+ Cell Counts in HIV-Infected Persons in Argentina. PLoS One. 2016; 11(7):e0160082. PMC: 4965084. DOI: 10.1371/journal.pone.0160082. View

3.
Pasha S, Pasha S, Suhasini T, Rao D . Hepatitis E Virus-Associated Acute Encephalitic Parkinsonism. J Assoc Physicians India. 2018; 66(3):92-3. View

4.
Myint K, Endy T, Gibbons R, Laras K, Mammen Jr M, Sedyaningsih E . Evaluation of diagnostic assays for hepatitis E virus in outbreak settings. J Clin Microbiol. 2006; 44(4):1581-3. PMC: 1448661. DOI: 10.1128/JCM.44.4.1581-1583.2006. View

5.
Mirazo S, Mainardi V, Ramos N, Gerona S, Rocca A, Arbiza J . Indigenous hepatitis E virus genotype 1 infection, Uruguay. Emerg Infect Dis. 2014; 20(1):171-3. PMC: 3884737. DOI: 10.3201/eid2001.131471. View